CTLA4 and colitis: Their work provides critical evidence for the utility of an Fc domain‐lacking anti‐CTLA‐4 antibody, either alone or combined with anti‐PD‐1 or anti‐PD‐L1 antibodies in effectively stimulated antitumor responses, but not causing colitis, presenting potential benefits to the suffering cancer patients in clinical settings (Figure 1).